Dako, BMS partner for pharmacodiagnostics
This article was originally published in Clinica
Executive Summary
Dako has agreed to develop diagnostic tests which will be used to identify patients more likely to benefit from cancer treatment drugs that are being developed by Bristol-Myers Squibb (BMS). Glostrup, Denmark-based Dako specialises in tissue-based cancer diagnostics – its pharmDx business also develops companion tests for other pharmaceutical companies such as Roche, Genentech and OSI Pharmaceuticals, among others.